Myriad Genetics won a significant victory last month when an appeals court upheld the company's gene patents. But now, The New York Times' Andrew Pollack says, the real battle starts for Myriad. Some experts say the company's test for the BRCA1 and BRCA2 mutations is "technologically outmoded, incomplete and too costly," Pollack reports.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.